Pdt Partners, LLC Travere Therapeutics, Inc. Transaction History

Pdt Partners, LLC

$1.02 Billion
Q3 2024

A detailed history of Pdt Partners, LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 264,273 shares of TVTX stock, worth $4.88 Million. This represents 0.36% of its overall portfolio holdings.

Number of Shares

264,273

Previous 238,783 10.67%

Holding current value

$4.88 Million

Previous $1.96 Million 88.43%

% of portfolio

0.36%

Previous 0.2%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$7.89 - $15.21 $201,116 - $387,702	25,490 Added 10.67%	264,273 $3.7 Million
Q2 2024 Aug 15, 2024	BUY	$5.26 - $8.28 $227,452 - $358,043	43,242 Added 22.11%	238,783 $1.96 Million
Q1 2024 May 15, 2024	BUY	$7.18 - $9.82 $962,263 - $1.32 Million	134,020 Added 217.84%	195,541 $1.51 Million
Q4 2023 Feb 14, 2024	BUY	$5.44 - $9.5 $334,674 - $584,449	61,521 New	61,521 $553,000
Q2 2023 Aug 14, 2023	SELL	$15.3 - $22.61 $364,905 - $539,248	-23,850 Reduced 50.01%	23,845 $366,000
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $849,924 - $1.09 Million	47,695 New	47,695 $1.07 Million
Q2 2022 Aug 15, 2022	SELL	$20.94 - $30.01 $263,383 - $377,465	-12,578 Reduced 11.49%	96,905 $2.35 Million
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $2.27 Million - $2.95 Million	96,274 Added 728.85%	109,483 $2.82 Million
Q4 2021 Feb 14, 2022	BUY	$24.34 - $31.17 $321,507 - $411,724	13,209 New	13,209 $410,000
Q1 2021 May 17, 2021	SELL	$23.37 - $31.77 $667,517 - $907,446	-28,563 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$19.17 - $27.87 $547,552 - $796,050	28,563 New	28,563 $778,000

Others Institutions Holding TVTX

# of Institutions

194

Shares Held

83.7M

Call Options Held

776K

Put Options Held

900K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.19B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account